0	10	Lymphocyte	Lymphocyte	NNP
11	15	cell	cell	NN
16	21	lines	line	NNS
22	26	from	from	IN
27	34	vitamin	vitamin	NN
35	46	D-dependent	d-dependent	JJ
47	54	rickets	ricket	NNS
55	59	type	type	NN
60	62	II	ii	CD
63	67	show	show	VBP
68	78	functional	functional	JJ
79	86	defects	defect	NNS
87	89	in	in	IN
90	93	the	the	DT
94	95	1	1	CD
96	121	alpha,25-dihydroxyvitamin	alpha,25-dihydroxyvitamin	NN
122	124	D3	d3	NN
125	133	receptor	receptor	NN
133	134	.	.	.

136	146	Lymphocyte	Lymphocyte	NNP
147	151	cell	cell	NN
152	157	lines	line	NNS
158	162	were	be	VBD
163	174	established	establish	VBN
175	179	from	from	IN
180	184	five	five	CD
185	193	patients	patient	NNS
194	198	with	with	IN
199	206	vitamin	vitamin	NN
207	218	D-dependent	d-dependent	JJ
219	226	rickets	ricket	NNS
226	227	,	,	,
228	232	type	type	NN
233	235	II	ii	CD
236	237	(	(	(
237	244	VDDR-II	VDDR-II	NNP
244	245	)	)	)
245	246	.	.	.

247	252	These	these	DT
253	258	lines	line	NNS
259	263	were	be	VBD
264	275	established	establish	VBN
276	278	by	by	IN
279	288	infection	infection	NN
289	293	with	with	IN
294	299	human	human	JJ
300	315	T-lymphotrophic	t-lymphotrophic	JJ
316	321	virus	virus	NN
322	326	type	type	NN
327	328	I	i	CD
329	330	(	(	(
330	336	HTLV-I	HTLV-I	NNP
336	337	)	)	)
337	338	.	.	.

339	346	Binding	binding	NN
347	349	of	of	IN
350	351	[	[	(
351	355	3H]1	3h]1	NN
356	381	alpha,25-dihydroxyvitamin	alpha,25-dihydroxyvitamin	NN
382	384	D3	d3	NN
385	386	(	(	(
386	398	1,25(OH)2D3)	1,25(oh)2d3)	NN
399	401	to	to	TO
402	405	its	its	PRP$
406	414	receptor	receptor	NN
415	417	in	in	IN
418	423	these	these	DT
424	428	cell	cell	NN
429	434	lines	line	NNS
435	438	was	be	VBD
439	447	compared	compare	VBN
448	450	to	to	TO
451	458	binding	bind	VBG
459	466	studies	study	NNS
467	472	using	use	VBG
473	474	a	a	DT
475	487	T-lymphocyte	T-lymphocyte	NNP
488	492	cell	cell	NN
493	497	line	line	NN
498	499	(	(	(
499	504	S-LB1	S-LB1	NNP
504	505	)	)	)
506	510	from	from	IN
511	512	a	a	DT
513	519	normal	normal	JJ
520	531	individual.	individual.	NN
532	535	The	the	DT
536	547	1,25(OH)2D3	1,25(oh)2d3	NN
548	556	receptor	receptor	NN
557	559	of	of	IN
560	565	S-LB1	S-LB1	NNP
566	569	was	be	VBD
570	580	comparable	comparable	JJ
581	583	to	to	TO
584	587	the	the	DT
588	606	well-characterized	well-characterized	JJ
607	612	chick	chick	NN
613	623	intestinal	intestinal	JJ
624	635	1,25(OH)2D3	1,25(oh)2d3	NN
636	644	receptor	receptor	NN
645	647	in	in	IN
648	653	terms	term	NNS
654	656	of	of	IN
657	660	its	its	PRP$
661	667	ligand	ligand	NN
668	675	binding	binding	NN
676	684	affinity	affinity	NN
685	688	and	and	CC
689	697	capacity	capacity	NN
697	698	,	,	,
699	702	its	its	PRP$
703	711	mobility	mobility	NN
712	714	on	on	IN
715	719	5-20	5-20	CD
719	720	%	%	NN
721	728	sucrose	sucrose	NN
729	738	gradients	gradient	NNS
738	739	,	,	,
740	743	and	and	CC
744	747	its	its	PRP$
748	758	adsorption	adsorption	NN
759	761	to	to	TO
762	765	and	and	CC
766	773	elution	elution	NN
774	784	properties	property	NNS
785	789	from	from	IN
790	803	DNA-cellulose	DNA-cellulose	NNP
803	804	.	.	.

805	810	Three	three	CD
811	815	cell	cell	NN
816	821	lines	line	NNS
822	833	established	establish	VBN
834	838	from	from	IN
839	847	patients	patient	NNS
848	852	with	with	IN
853	860	VDDR-II	VDDR-II	NNP
861	862	(	(	(
862	868	Rh-VDR	Rh-VDR	NNP
868	869	,	,	,
870	876	Sh-VDR	Sh-VDR	NNP
876	877	,	,	,
878	881	and	and	CC
882	888	Ab-VDR	Ab-VDR	NNP
888	889	)	)	)
890	896	showed	show	VBD
897	899	no	no	DT
900	908	specific	specific	JJ
909	916	binding	binding	NN
917	919	of	of	IN
920	931	1,25(OH)2D3	1,25(oh)2d3	NN
932	934	to	to	TO
935	936	a	a	DT
937	945	receptor	receptor	NN
946	949	and	and	CC
950	959	treatment	treatment	NN
960	962	of	of	IN
963	966	the	the	DT
967	975	cultured	culture	VBN
976	981	cells	cell	NNS
982	986	with	with	IN
987	998	1,25(OH)2D3	1,25(OH)2D3	NNP
999	1002	did	do	VBD
1003	1006	not	not	RB
1007	1016	stimulate	stimulate	VB
1017	1027	production	production	NN
1028	1030	of	of	IN
1031	1054	24,25-dihydroxy-vitamin	24,25-dihydroxy-vitamin	NN
1055	1057	D3	D3	NNP
1058	1059	(	(	(
1059	1072	24,25(OH)2D3)	24,25(OH)2D3)	NNP
1072	1073	,	,	,
1074	1075	a	a	DT
1076	1084	response	response	NN
1085	1090	which	which	WDT
1091	1093	is	be	VBZ
1094	1104	diagnostic	diagnostic	JJ
1105	1107	of	of	IN
1108	1111	the	the	DT
1112	1120	presence	presence	NN
1121	1123	of	of	IN
1124	1125	a	a	DT
1126	1136	functional	functional	JJ
1137	1148	1,25(OH)2D3	1,25(oh)2d3	NN
1149	1157	receptor	receptor	NN
1157	1158	.	.	.

1159	1161	In	in	IN
1162	1163	a	a	DT
1164	1170	fourth	fourth	JJ
1171	1175	cell	cell	NN
1176	1180	line	line	NN
1180	1181	,	,	,
1182	1188	A1-VDR	A1-VDR	NNP
1188	1189	,	,	,
1190	1193	the	the	DT
1194	1202	receptor	receptor	NN
1203	1206	for	for	IN
1207	1218	1,25(OH)2D3	1,25(OH)2D3	NNP
1219	1222	had	have	VBD
1223	1224	a	a	DT
1225	1228	low	low	JJ
1229	1236	binding	binding	NN
1237	1245	capacity	capacity	NN
1246	1249	and	and	CC
1250	1273	25(OH)D3-24-hydroxylase	25(oh)d3-24-hydroxylase	NN
1274	1282	activity	activity	NN
1283	1286	was	be	VBD
1287	1290	not	not	RB
1291	1301	detectable	detectable	JJ
1301	1302	.	.	.

1303	1312	Induction	Induction	NNP
1313	1315	of	of	IN
1316	1329	24,25-(OH)2D3	24,25-(oh)2d3	NN
1330	1339	synthesis	synthesis	NN
1340	1342	by	by	IN
1343	1354	1,25(OH)2D3	1,25(OH)2D3	NNP
1355	1358	was	be	VBD
1359	1367	observed	observe	VBN
1368	1370	in	in	IN
1371	1374	the	the	DT
1375	1380	fifth	fifth	JJ
1381	1385	cell	cell	NN
1386	1390	line	line	NN
1390	1391	,	,	,
1392	1402	designated	designate	VBN
1403	1409	Ro-VDR	Ro-VDR	NNP
1409	1410	,	,	,
1411	1419	although	although	IN
1420	1423	the	the	DT
1424	1435	sensitivity	sensitivity	NN
1436	1438	to	to	TO
1439	1446	hormone	hormone	NN
1447	1456	treatment	treatment	NN
1457	1460	was	be	VBD
1461	1466	lower	low	JJR
1467	1471	than	than	IN
1472	1474	in	in	IN
1475	1478	the	the	DT
1479	1486	control	control	NN
1487	1491	cell	cell	NN
1492	1496	line	line	NN
1497	1501	from	from	IN
1502	1503	a	a	DT
1504	1510	normal	normal	JJ
1511	1516	donor	donor	NN
1516	1517	.	.	.

1518	1521	The	the	DT
1522	1530	capacity	capacity	NN
1531	1533	of	of	IN
1534	1537	the	the	DT
1538	1546	receptor	receptor	NN
1547	1550	for	for	IN
1551	1562	1,25(OH)2D3	1,25(OH)2D3	NNP
1563	1566	was	be	VBD
1567	1570	low	low	JJ
1571	1573	in	in	IN
1574	1580	Ro-VDR	Ro-VDR	NNP
1580	1581	.	.	.

1582	1584	In	in	IN
1585	1588	all	all	DT
1589	1593	cell	cell	NN
1594	1599	lines	line	NNS
1600	1605	where	where	WRB
1606	1617	1,25(OH)2D3	1,25(oh)2d3	NN
1618	1625	binding	bind	VBG
1626	1628	to	to	TO
1629	1630	a	a	DT
1631	1639	receptor	receptor	NN
1640	1643	was	be	VBD
1644	1654	detectable	detectable	JJ
1654	1655	,	,	,
1656	1659	the	the	DT
1660	1668	receptor	receptor	NN
1669	1672	had	have	VBD
1673	1676	the	the	DT
1677	1684	typical	typical	JJ
1685	1698	sedimentation	sedimentation	NN
1699	1710	coefficient	coefficient	NN
1711	1713	of	of	IN
1714	1717	3.7	3.7	CD
1718	1719	S	S	NNP
1720	1722	on	on	IN
1723	1730	sucrose	sucrose	NN
1731	1738	density	density	NN
1739	1747	gradient	gradient	NN
1748	1756	analysis	analysis	NN
1756	1757	.	.	.

1758	1765	Binding	binding	NN
1766	1769	and	and	CC
1770	1777	elution	elution	NN
1778	1788	properties	property	NNS
1789	1791	to	to	TO
1792	1805	DNA-cellulose	dna-cellulose	NN
1805	1806	,	,	,
1807	1814	however	however	RB
1814	1815	,	,	,
1816	1824	differed	differ	VBD
1825	1829	from	from	IN
1830	1836	normal	normal	JJ
1837	1839	in	in	IN
1840	1844	both	both	CC
1845	1851	Ro-VDR	Ro-VDR	NNP
1852	1855	and	and	CC
1856	1862	A1-VDR	A1-VDR	NNP
1863	1868	cells	cell	NNS
1869	1874	where	where	WRB
1875	1882	elution	elution	NN
1883	1887	from	from	IN
1888	1901	DNA-cellulose	DNA-cellulose	NNP
1902	1910	occurred	occur	VBD
1911	1913	at	at	IN
1914	1915	a	a	DT
1916	1921	lower	low	JJR
1922	1926	salt	salt	NN
1927	1940	concentration	concentration	NN
1941	1945	than	than	IN
1946	1948	is	be	VBZ
1949	1956	typical	typical	JJ
1957	1959	of	of	IN
1960	1963	the	the	DT
1964	1975	1,25(OH)2D3	1,25(oh)2d3	NN
1976	1984	receptor	receptor	NN
1984	1985	.	.	.

1986	1991	While	while	IN
1992	1998	Ro-VDR	Ro-VDR	NNP
1999	2004	cells	cell	NNS
2005	2011	showed	show	VBD
2012	2019	typical	typical	JJ
2020	2027	nuclear	nuclear	JJ
2028	2040	localization	localization	NN
2041	2043	of	of	IN
2044	2047	the	the	DT
2048	2058	unoccupied	unoccupied	JJ
2059	2070	1,25(OH)2D3	1,25(oh)2d3	NN
2071	2079	receptor	receptor	NN
2079	2080	,	,	,
2081	2088	neither	neither	CC
2089	2092	the	the	DT
2093	2103	unoccupied	unoccupied	JJ
2104	2107	nor	nor	CC
2108	2111	the	the	DT
2112	2120	occupied	occupied	JJ
2121	2129	receptor	receptor	NN
2130	2134	from	from	IN
2135	2141	A1-VDR	A1-VDR	NNP
2142	2147	cells	cell	NNS
2148	2151	was	be	VBD
2152	2162	completely	completely	RB
2163	2172	localized	localize	VBN
2173	2175	in	in	IN
2176	2179	the	the	DT
2180	2187	nucleus	nucleus	NN
2187	2188	.	.	.

2189	2191	In	in	IN
2192	2193	a	a	DT
2194	2200	series	series	NN
2201	2203	of	of	IN
2204	2214	functional	functional	JJ
2215	2222	studies	study	NNS
2223	2225	we	we	PRP
2226	2231	found	find	VBD
2232	2236	that	that	IN
2237	2247	modulation	modulation	NN
2248	2250	of	of	IN
2251	2254	the	the	DT
2255	2260	level	level	NN
2261	2263	of	of	IN
2264	2267	the	the	DT
2268	2273	mRNAs	mrna	NNS
2274	2280	coding	cod	VBG
2281	2284	for	for	IN
2285	2289	both	both	CC
2290	2293	the	the	DT
2294	2299	c-myc	c-myc	NN
2300	2308	oncogene	oncogene	NN
2309	2312	and	and	CC
2313	2316	the	the	DT
2317	2323	growth	growth	NN
2324	2330	factor	factor	NN
2331	2336	known	know	VBN
2337	2339	as	as	IN
2340	2360	granulocyte-monocyte	granulocyte-monocyte	NN
2361	2367	colony	colony	NN
2368	2379	stimulating	stimulating	NN
2380	2388	activity	activity	NN
2389	2391	by	by	IN
2392	2403	1,25(OH)2D3	1,25(oh)2d3	NN
2404	2414	correlated	correlate	VBD
2415	2419	with	with	IN
2420	2423	the	the	DT
2424	2435	1,25(OH)2D3	1,25(oh)2d3	NN
2436	2444	receptor	receptor	NN
2445	2451	status	status	NN
2452	2454	of	of	IN
2455	2460	these	these	DT
2461	2466	cells	cell	NNS
2466	2467	.	.	.

2468	2471	Use	use	NN
2472	2474	of	of	IN
2475	2480	these	these	DT
2481	2485	cell	cell	NN
2486	2491	lines	line	NNS
2492	2496	will	will	MD
2497	2507	facilitate	facilitate	VB
2508	2515	further	further	JJ
2516	2521	study	study	NN
2522	2524	of	of	IN
2525	2528	the	the	DT
2529	2538	molecular	molecular	JJ
2539	2548	defect(s)	defect(s)	NN
2549	2551	in	in	IN
2552	2555	the	the	DT
2556	2564	receptor	receptor	NN
2565	2568	for	for	IN
2569	2580	1,25(OH)2D3	1,25(oh)2d3	NN
2581	2583	in	in	IN
2584	2591	vitamin	vitamin	NN
2592	2603	D-dependent	d-dependent	JJ
2604	2611	rickets	ricket	NNS
2612	2616	type	type	NN
2617	2619	II	ii	CD
2620	2623	and	and	CC
2624	2628	will	will	MD
2629	2634	allow	allow	VB
2635	2636	a	a	DT
2637	2648	correlation	correlation	NN
2649	2653	with	with	IN
2654	2664	impairment	impairment	NN
2665	2667	of	of	IN
2668	2676	cellular	cellular	JJ
2677	2686	functions	function	NNS
2686	2687	.	.	.